Zhengye Biotechnology (ZYBT) Stock Price, News & Analysis

Company Overview

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

Key Stats

• Today's Range: $9.50 to $12.46
• 50-Day Range: $3.64 to $10.55
• 52-Week Range: $3.50 to $12.46
• Volume: 599,368 shs
• Average Volume: 274,433 shs
• Market Capitalization: $492.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ZYBT Stock Analysis - Frequently Asked Questions

How have ZYBT shares performed this year?

Zhengye Biotechnology's stock was trading at $4.86 at the beginning of 2025. Since then, ZYBT shares have increased by 114.8% and is now trading at $10.44.
View the best growth stocks for 2025 here.

When did Zhengye Biotechnology IPO?

Zhengye Biotechnology (ZYBT) raised $6 million in an initial public offering (IPO) on Tuesday, January 7th 2025. The company issued 1,500,000 shares at a price of $4.00 per share. Kingswood Capital Partners acted as the underwriter for the IPO.

How do I buy shares of Zhengye Biotechnology?

Shares of ZYBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 4/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ZYBT
• Previous Symbol: NASDAQ:ZYBT
• CIK: 1975641
• Web: www.jlzybio.com
• Phone: 86-13844801919
• Fax: N/A
• Employees: 278
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $189.75 million
• Price / Sales: 2.60
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 47,166,000
• Free Float: N/A
• Market Cap: $492.41 million
• Optionable: N/A
• Beta: N/A